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Aim To determine the prognostic value of baseline red 
blood cell distribution width (RDW) in diffuse large B cell 
lymphoma (DLBCL) patients.
Methods Data from 81 DLBCL patients diagnosed from 
2006 to 2013 at the University Hospital Center Osijek, 
Osijek, Croatia, were reviewed. We evaluated disease out-
come, overall survival (OS) and event-free survival (EFS), 
and demographic, clinical and laboratory factors affecting 
outcome. Univariate analysis and Cox regression analysis 
were used.
Results Median age of patients was 64 years, 29 were 
men (35.8%). Higher RDW levels (%) were found in pa-
tients with advanced Ann Arbor clinical stage (14.94 ± 1.82 
vs 13.55 ± 1.54, P = 0.001) and in those with poor response 
to therapy (14.94 ± 1.82 vs 13.55 ± 1.54, P = 0.001). Patients 
with RDW>15% (cut-off was calculated by receiver oper-
ating characteristics) had significantly worse OS (median 
[range], 33 months [20-46] vs 74 months [65-82], P < 0.001) 
and EFS (27 months [15-40] vs 68 months [59-77], P < 0.001). 
Cox regression analysis showed that RDW>15% was an 
independent prognostic factor for OS (HR 3.654, 95% CI 
1.128-11.836) and EFS (HR 2.611, 95% CI 1.012-6-739).
Conclusion High baseline RDW is an independent prog-
nostic marker of poor outcome in patients with DLBCL. 
RDW could be an easily available and inexpensive marker 
for the risk stratification in patients with DLBCL.
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Red cell distribution width (RDW) is analyzed routinely as 
part of the complete blood count (CBC). It is a measure of 
heterogeneity of the red blood cell (RBC) size and tradition-
ally has played a role in the differential diagnosis of anemia 
(1). High RDW values are associated with increased mortal-
ity in general population and in patients with cardiovas-
cular disease, sepsis, acute kidney injury, chronic obstruc-
tive pulmonary disease, hepatitis B, and those on chronic 
dialysis (2-9). There is also evidence of its prognostic val-
ue in various malignancies (10-14). A recent study found 
a strong relation between high RDW and poor survival in 
patients with lung cancer (15). RDW was also found to be 
a significant predictor of poor prognosis in patients with 
malignant mesothelioma (16). In patients with symptom-
atic multiple myeloma, elevated RDW values were associ-
ated with a higher stage disease according to International 
Staging System and poor prognosis (17). The mechanism 
that could explain the relation between RDW and survival 
or disease activity is not clear, but it is considered that high 
RDW is caused by chronic inflammation, poor nutritional 
status, oxidative stress, and age-related diseases that lead 
to changes in erythropoiesis (2,18-20).
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon group of lymphomas, amounting to 25% of all non-
Hodgkin’s lymphomas (NHL) (21). It is a type of aggressive 
lymphoma that usually affects middle-aged and elderly 
patients. The distribution of NHL subtypes in Croatia corre-
sponds to the European average (22). The most commonly 
used prognostic index in aggressive NHL is the internation-
al prognostic index (IPI) and its variants used in elderly pa-
tients (age-adjusted IPI) and in patients treated with ritux-
imab (R-IPI) (23,24).
So far, there have been no reports on the prognostic value 
of RDW in patients with DLBCL. The aim of our study was 
to determine whether RDW measured at diagnosis was an 
independent prognostic factor of disease outcome, overall 
survival (OS), and event-free survival (EFS) in patients with 
DLBCL.
MethodS
This retrospective study included registry data on 81 pa-
tients with histologically verified nodal and extranodal DL-
BCL, diagnosed between November 2006 and December 
2013 at the tertiary care University Hospital Centre Osijek. 
The study included patients who were in clinical stage II-IV 
by Ann Arbor (AA) staging, or IE or I bulky shape, who were 
initially planned for at least 4 cycles of chemotherapy and 
who had complete clinical data. Exclusion criteria includ-
ed transformed indolent lymphoma and primary DLBCL of 
the central nervous system (CNS).
The following Demographic characteristics, clinical fea-
tures, and laboratory parameters were collected from 
medical records: AA stage, IPI, B symptoms, comorbidity, 
serum lactate dehydrogenase (LDH), serum C-reactive pro-
tein (CRP), serum albumin, RBC, serum hemoglobin con-
centration (Hgb), mean corpuscular volume (MCV), white 
blood cells count (WBC), platelet count, absolute lympho-
cyte count (ALC), serum ferritin, RDW, Eastern Cooperative 
Oncology Group performance status (ECOG PS), and re-
sponse to therapy.
Disease staging was done according to the AA classifica-
tion. Performance status was quantified using ECOG. Most 
of the patients (90%) were treated with standard immuno-
chemoterapy: rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone (R-CHOP) regimen, and others 
by R-CHOP and CHOP-like regimens.
The outcomes were response to treatment, EFS, and OS. In 
patients in whom treatment was initiated and completed, 
the response to the therapy was determined by the Inter-
national Working Group response criteria (25). EFS started 
from the first day of diagnosis to one of the events: disease 
progression, initiation of another anti-lymphomas treat-
ment, relapse, death due to any cause, or until the latest 
control. OS refereed to period from date of the diagnosis 
until the date of death due to any cause or to the date of 
the latest control.
Initial values of RDW and of other laboratory parameters 
were defined as values obtained within 2 weeks before a 
front line-treatment. CBC including RDW calculation was 
determined from whole blood with K2 EDTA or K3 EDTA as 
an anticoagulant on Adiva 2100 analyzer (Siemens Health-
care Diagnostics, Tarrytown, NY, USA). RDW values were 
categorized based on the reference range in our laborato-
ry, which is between 9%-15%, ie, the patients were divided 
in two groups using the cut-off value of 15%. The cut off 
value obtained by receiver operating characteristics (ROC) 
analysis was also 15%.
Statistical analysis
SPSS (version 15.0, SPSS Inc. Chicago, IL, USA) and Med-
Calc Statistical Software, version 11.4.2.0 (Ostend, Bel-
gium) were used. Variables were tested for normal-
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ity using Kolmogorov-Smirnov test. Continuous variables 
with normal distribution were expressed as mean ± stan-
dard deviation (SD) and those with not normal distribution 
as median and interquartile range (IQR). Categorical vari-
ables were compared by χ2 test or Fisher exact test. Two 
continuous independent variables were analyzed by t test 
for normally distributed variables and by non-parametric 
Mann-Whitney U test for not normally distributed vari-
ables. More than two independent samples were analyzed 
using one-way analysis of variance (ANOVA) or Kruskal-
Wallis test. Correlation was assessed using Pearson or 
Spearman test, as appropriate. Survival was analyzed with 
Kaplan-Meier curves and survival variables were compared 
with log-rank test. To estimate the predictive value of RDW 
we used Cox regression univariate and multivariate analy-
sis. ROC analysis was used to determine the cut-off value 
of RDW for mortality. P value <0.05 was considered statisti-
cally significant.
ReSuLtS
The total number of eligible patients with DLBCL was 87. 
Six patients were excluded (2 who were in AA stage I, 1 
due to insufficient clinical data, 1 due to transformed indo-
lent lymphoma, and 2 for primary CNS disease). Fifty two 
patients were women and median age of all patients was 
64 years (IQR 52.5-72.5 years). Median RDW was 14.3% (IQR 
13.25%-15.55%). There was a significant positive correla-
tion between RDW and CRP, IPI, ECOG PS, and clinical stage 
(rS = 0.388, P < 0.001; rS = 0.551, P < 0.001; rS = 0.284, P = 0.01; 
FIguRe 1. Correlation between red blood distribution width (RdW) and (A) C-reactive protein; (B) red blood cells count; (C) hemo-
globin concentration; (D) albumin concentration in patients with diffuse large B-cell lymphoma.
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rS = 0.384, P = 0.001, respectively) and negative significant 
correlation between RBC, Hgb, and serum albumin con-
centration (r = -0.433, P < 0.001; r = -0.54, P < 0.001; r = -0.583, 
P < 0.001, respectively) (Figure 1). We found no correlation 
between RDW and WBC, ALC, platelet count, serum creati-
nine, and serum ferritin concentrations. Patients with high-
er AA stage (III and IV) had higher RDW values compared to 
patients with lower AA stages (stage I and II) (14.94 ± 1.82% 
vs 13.55 ± 1.54%, P = 0.001, t test, Figure 2).
RDW values differed significantly between groups accord-
ing to treatment outcome (complete remission vs par-
tial remission vs no response-progression, 13.93 ± 1.78 vs 
15.46 ± 1.34 vs 15.77 ± 1.47, P < 0.001, ANOVA, Figure 3A). In 
patients treated with immunochemotherapy (N = 77) RDW 
values also differed significantly between groups accord-
ing to treatment outcome (13.95 ± 1.79 vs 15.46 ± 1.34 vs 
15.98 ± 1.44, P < 0.001, ANOVA, Figure 3C). Patients who re-
sponded to therapy had lower RDW values than those who 
did not respond to therapy (13.55 ± 1.54% vs 14.94 ± 1.82%, 
P = 0.001, t test, Figure 3B).
According to both ROC analysis and the reference range 
for RDW in our laboratory, the patients were divided into 
two groups. Area under the curve (AUC) for RDW was 0.768 
(95% CI 0.661-0.855, Z = 4.724), optimal cut-off value was 
15%, with 72.7% sensitivity and 79.7% specificity, P < 0.001 
(Figure 4). 53 patients had normal RDW (≤15%) and 28 
patients had elevated RDW (>15%). The patients with el-
evated RDW had significantly lower ECOG PS (P < 0.001), 
FIguRe 2. Baseline red blood cell distribution width (RdW). Pa-
tients with diffuse large B-cell lymphoma (N = 81) were divided 
according to Ann Arbor clinical staging.
FIguRe 3. Baseline red blood cell distribution width (RdW) in 
patients with diffuse large B-cell lymphoma (dLBCL) (N = 80) 
(A) according to the treatment outcome and (B) according to 
response to the treatment; (C) in patients with dLBCL treated 
with immunochemotherapy according to the treatment 
outcome (N = 77).
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tABLe 1. Patient baseline characteristics (overall and divided according to 15% RdW cutoff)*
divided by RdW (%)
Variable overall normal (≤15) (n = 53) elevated (>15) (n = 28) P
RdW (%), mean±Sd  14.44 ± 1.84  13.44 ± 1  16.35 ± 1.54 <0.001†
Age in years, median (IQR)  64 (52.5-72.5)  62 (50.5-75)  69 (62-72) 0.137†
Age group, n (%)
≤60 years  31 (38.3)  25 (47.2)   6 (21.4) 0.023‡
>60 years  50 (61.7)  28 (52.8)  22 (78.6)
Sex, n (%)
male  29 (35.8)  18 (34)  11 (39.3) 0.635‡
female  52 (64.2)  35 (66)  17 (60.7)
eCog PS, n (%)
<2  62 (76.5)  47 (88.7)  15 (53.6) <0.001‡
≥2  19 (23.5)   6 (11.3)  13 (46.4)
IPI, n (%)
≤2  46 (56.8)  41 (77.4)   5 (17.9) <0.001‡
>2  35 (43.2)  12 (22.6)  23 (82.1)
Ldh, n (%)
normal  44 (54.3)  38 (71.7)   6 (24.4) <0.001‡
>241 U/L  37 (45.7)  15 (28.3)  22 (78.6)
B symptoms II, n (%)
no  37 (45.7)  32 (60.4)   5 (17.9) <0.001‡
yes  44 (54.3)  21 (39.6)  23 (82.1)
Bone marrow infiltration, n (%)¶
no  51 (63.7)  39 (73.6)  12 (44.4) 0.01‡
yes  29 (36.3)  14 (26.4)  15 (55.6)
Ann Arbor clinical stage, n (%)
I and II  29 (35.8)  25 (47.2)   4 (14.3) 0.004‡
III and IV  52 (64.2)  28 (52.8)  24 (85.7)
Front line treatment, n (%)**
immunochemotherapy  77 (96.2)  51 (96.2)  26 (96.3) >0.999‡
chemotherapy   3 (3.7)   2 (3.8)   1 (3.7)
Comorbidity, n (%)
diabetes mellitus   6 (7.4)   5 (9.4)   1 (3.6) 0.659‡
hypertension  22 (27.2)  16 (30.2)   6 (21.4) 0.399‡
cardiovascular disease  12 (14.8)   7 (13.2)   5 (17.9) 0.575‡
chronic lung disease   1 (1.2)   0 (0)   1 (3.6) 0.346‡
chronic liver disease   1 (1.2)   1 (1.9)   0 (0) >0.999‡
malignancy   4 (4.9)   2 (3.8)   2 (7.1) 0.606‡
bleeding   2 (2.5)   0 (0)   2 (7.1) 0.117‡
RBC × 1012/L, mean±Sd   4.25 ± 0.64   4.44 ± 0.52   3.89 ± 0.71 0.001†
hemoglobin (g/L), mean±Sd 120.83 ± 19.46 128.71 ± 13.78 105.91 ± 20.07 <0.001†
MCV (fL), mean±Sd  85.78 ± 6.2  86.23 ± 6.27  84.93 ± 6.09 0.373†
WBC × 109/L, mean±Sd   7.18 ± 2.63   6.95 ± 2.38   7.61 ± 3.04 0.325†
ALC (cells ×109/L), mean±Sd   1.61 ± 0.93   1.7 ± 0.7   1.42 ± 0.73 0.099†
Platelet ×109/L, mean±Sd 262.49 ± 124.15 246.79 ± 118.56 292.21 ± 131.15 0.118†
CRP (mg/L), median (IQR)   9.4 (3.9-31)   6 (3.05-13.15)  24.55 (8.48-46.9) 0.001§
Albumin (g/L), mean±Sd  41.03 ± 6.42  44.01 ± 4.77  35.38 ± 5.25 <0.001†
Iron (µmol/L), mean±Sd  10.41 ± 6.73  11.73 ± 6.68   7.96 ± 6.2 0.016†
Ferritin (µg/L), median (IQR)  97.25 (49.65-268.1)  85.85 (46.3-168.15) 134.2 (64.1-513.53) 0.05§
treatment outcome, n (%)**
response  65 (81.2)  50 (94.3)  15 (55.6) <0.001‡
no response  15 (18.8)   3(5.7)  12 (44.4)
*RdW – red blood cell distribution width; Sd – standard deviation; IQR – interquartile range; eCog PS – eastern Cooperative oncology group 
performance status; IPI – International prognostic index; Ldh – lactate dehydrogenase; RBC – red blood cells; MCV – mean corpuscular volume; WBC 




IIfever, night sweat, weight loss.
¶in one patient there was no information about bone marrow infiltration.
**in one patient the lethal outcome occurred before the planned treatment.
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higher AA stage (P = 0.004), higher IPI (P < 0.001), higher 
CRP (P = 0.001), lower RBC (P = 0.001), lower serum Hgb 
(P < 0.001), lower albumin concentration (P < 0.001), poor-
er response to treatment (P < 0.001), more frequent ex-
pressed B symptoms (P < 0.001), and had infiltration of 
bone marrow (P = 0.01), and more often were older than 
60 years (P = 0.023). Front line treatment, comorbidity, and 
serum ferritin concentrations did not differ significantly be-
tween the groups (Table 1).
Survival and prognostic factors
Median follow-up was 22 months (IQR 8.5-37.5 months), 
22 (27.2%) patients died, and 27 (33.3%) experienced one 
of the events. 5-year OS was 67.9% for all patients, signifi-
cantly lower in those with elevated RDW (36.6% vs 79.4%, 
P < 0.001, log-rank test) (Figure 5). Patients with elevated 
RDW had shorter expected OS than patients with normal 
RDW (33 months [20-46] vs 74 months [65-82], P < 0.001, 
log-rank test). 5-year EFS was 55.6% for all patients, signifi-
cantly lower in those with elevated RDW (17.1% vs 74.7%, 
P < 0.001, log-rank test) (Figure 6). Patients with elevated 
RDW had shorter expected EFS than patients with normal 
RDW (27 months [15-40] vs 68 months [59-77], P < 0.001, 
log-rank test). Univariate Cox-regression analysis showed 
that prognostic factors for OS were elevated RDW level 
(P < 0.001), age (P = 0.019), sex (male, P = 0.038), high ECOG 
PS (≥2, P < 0.001), high IPI (>2, P = 0.001), elevated LDH 
values (P = 0.002), and high clinical stage (stage III and IV, 
P = 0.011) (Table 2). Independent prognostic factors for EFS 
were elevated RDW level (P < 0.001), age (P = 0.006), high 
ECOG PS (≥2, P = 0.001), high IPI (>2, P < 0.001), elevated 
LDH values (P = 0.003), and high clinical stage (stage III and 
IV, P = 0.023) (Table 2). In the multivariate model RDW>15% 
was found to be an independent prognostic factor of OS 
(HR 3.654, 95% CI 1.128-11.386, P = 0.031) and EFS (HR 
2.611, 95% CI 1.012-6.739) (Table 2). Lower ECOG PS was 
an independent prognostic factor for OS (HR 3.497, 95% CI 
1.265-9.669, P = 0.016).
dISCuSSIoN
This study showed that increased RDW at diagnosis of DLB-
CL was associated with poor prognosis. To our knowledge, 
this is the first report on the prognostic value of RDW in 
patients with DLBCL. We showed that RDW was an inde-
pendent prognostic factor for OS and EFS.
Elevated RDW was associated with poor PS, advanced 
clinical stage by AA, higher CRP, and lower albumin. The 
results support the idea that high levels of RDW reflect 
chronic inflammation and poor nutritional status in pa-
tients with DLBCL. Accordingly, there was a positive 
correlation between RDW and CRP and a negative 
FIguRe 4. Receiver operating characteristic curve (RoC) of red 
cell distribution width (RdW) for differentiating overall survival 
in patients with diffuse large B-cell lymphoma (dLBCL) (N = 81).
FIguRe 5. Survival curve for overall survival according to baseline red cell distribu-
tion width (RdW) (normal ≤15%, elevated >15%) in patients with diffuse large 
B-cell lymphoma (N = 81).
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correlation between RDW and albumin. To our knowledge, 
no study has investigated the association between malnu-
trition and RDW in patients with DLBCL. Therefore, the re-
sults of the present study are important, indicating signifi-
cant association not only between RDW and CRP but also 
between RDW and hypoalbuminemia, which is indicative 
of malnutrition and mortality. It might be that inflamma-
tion and malnutrition impair erythropoiesis and thus con-
tribute to the increase in RDW. Future studies are needed 
to elucidate if this, at least in part, explains the nature of 
the association between mortality and elevated RDW in 
patients with DLBCL. Earlier research found association be-
tween RDW and a variety of inflammatory markers, such 
as high sensitive CRP, erythrocyte sedimentation rate, IL-6, 
soluble transferrin receptor, soluble TNF receptor I, and 
soluble TNF receptor II (26). In our study, RDW value did 
not correlate with ferritin concentration. Patients with val-
ues of RDW>15% did not have significantly higher value 
of ferritin. This is an unexpected finding, because ferritin is 
one of the parameters of inflammation. However, in some 
patients with impaired liver function ferritin may not be a 
positive marker of inflammation. Except for albumin serum 
concentration, we did not analyze liver function. Similarly, 
in chronic hemodialysis patients significant association of 
CRP and albumin was found with RDW, but also lacking 
in correlation between RDW and ferritin (27). We found a 
positive association between clinical stage according to 
AA and RDW. This result might also reflect an association 
between RDW and increased inflammation or malnutrition 
caused by cancer progression.
Malignant tumors lead to chronic inflammation and mal-
nutrition (28). This systemic inflammatory response, which 
reflects both disease activity and the host’s innate re-
sponse to tumor, may explain most symptoms and signs 
reported by cancer patients, including weight loss, an-
orexia, fatigue, and cancer related anemia (29). In different 
solid tumors, as well as lymphomas, inflammatory markers, 
including leukocytes, neutrophils, lymphocytes, CRP, and 
neutrophil/lymphocyte ratio have been associated with 
higher mortality rates (30-37). The mechanism that could 
explain the associations of RDW with survival or disease 
activity has not been elucidated, but possible explanation 
is that high levels of RDW reflect an underlying inflamma-
tory state that impairs erythrocyte maturation and leads 
to inadequate production of the hormone erythropoietin, 
FIguRe 6. Survival curve for event free survival according to baseline red 
cell distribution width (RdW) (normal ≤15%, elevated >15%) in patients 
with diffuse large B-cell lymphoma (N = 81).
tABLe 2. univariate and multivariate analysis for overall survival (oS) and event free survival (eFS) in patients with diffuse large B-cell 
lymphoma (N = 81)*
univariate Multivariate





















RDW (>15) 7.146 2.758-18.517 <0.001 5.026 2.273-11.113 <0.001 3.654 1.128-11.836 0.031 2.611 1.012-6.739 0.047
Age (year) 1.048 1.008-1.09 0.019 1.051 1.014-1.089 0.006 - - 0.761 - - 0.305
Sex (male) 2.737 1.051-5.652 0.038 - - 0.076 - - 0.14 - - -
ECOG PS (≥2) 6.202 2.518-15.278 <0.001 4.195 1.868-9.421 0.001 3.497 1.265-9.669 0.016 - - 0.091
IPI (>2) 7.761 2.613-23.049 <0.001 5.387 2.261-12.835 <0.001 - - 0.374 - - 0.116
LDH (>241 U/L) 4.689 1.727-12.73 0.002 3.491 1.524-7.994 0.003 - - 0.556 - - 0.409
Clinical stage AA 
(III and IV)
6.623 1.546-28.378 0.011 3.097 1.170-8.203 0.023 - - 0.488 - - 0.974
*RdW – red blood cell distribution width; eCog PS – eastern Cooperative oncology group performance status; IPI – International prognostic index; 
Ldh – lactate dehydrogenase; AA – Ann Arbor.
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undernutrition (ie, deficiencies of nutrients, such as iron, 
vitamin B12, and folate), or oxidative damage as well as 
age associated diseases via changes in erythropoiesis (38). 
Our results are in accordance with findings on important 
roles of inflammation and malnutrition in tumor progres-
sion. Patients with elevated RDW had a poor response to 
treatment. Chronic inflammation is also reported to lead 
to an unfavorable response to chemotherapy (39,40). Poor 
survival in patients with elevated RDW might be due to 
chronic inflammation itself, or lack of response to chemo-
therapy. More research is needed to explain the relation-
ships of RDW with inflammation and response to cancer 
treatment.
Recently, a few studies investigated the prognostic val-
ue of RDW in patients with malignant disease. RDW was 
significantly higher in patients with breast cancer than in 
patients with fibroadenomas (10). RDW was useful in the 
differentiation of benign and malignant causes of biliary 
obstruction when using an optimized cut-off value (11). 
RDW was a significant prognostic factor in patients with 
malignant mesothelioma, prostate, lung cancer, and mul-
tiple myeloma (15-17,41). Our results are concordant with 
these findings. It is possible that RDW is a general prognos-
tic factor, common in various diseases.
A limitation of the study is its retrospective design and 
the fact that it was conducted in a single center. The 
obtained cut-off value should be externally validated 
within independent cohorts of patients in a preferably 
prospective study. Our patients underwent heteroge-
neous treatment regimens, but when we excluded the 
patients who were treated only by chemotherapy we 
confirmed that RDW had prognostic significance for 
treatment outcome in patients with DLBCL. Despite the 
limitations, this is the first study showing the prognostic 
value of RDW in patients with DLBCL with a long follow-
up period. In conclusion, RDW could be a new, easily ac-
cessible, and inexpensive biomarker for risk assessment 
in patients with DLBCL.
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